Psoriasis News and Research

Latest Psoriasis News and Research

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

New initiative aims to develop Global Psoriasis Atlas

While studies over the recent years have contributed to an improved understanding of psoriasis, there are still significant gaps in knowledge related to the epidemiology of this serious, chronic disease and trends in incidence over time. The World Health Organization, reported in 2013 that the worldwide prevalence of psoriasis is around 2%, but that studies in developed countries have declared prevalence rates of more than twice the global estimate at an average of 4.6% .

15 Apr 2014

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Crescendo Biologics Limited today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management. Founding seed investor Sofinnova Partners also contributed significantly to the round.

3 Apr 2014

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

A panel of leading experts representing different sectors of the health care community met to discuss the significant and underestimated burden psoriasis and psoriatic arthritis have on patients, the health care system and economy, and the impact medical innovation has on reducing these burdens.

1 Apr 2014

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Patients with an autoimmune disease have a 3.8-fold increased risk of developing epilepsy, according to a new population-level study from Boston Children's Hospital based on health insurance claim data.

1 Apr 2014

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children.

31 Mar 2014

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.

28 Mar 2014

Researchers discover novel population of neutrophils that exhibit enhanced microbial killing activity

Case Western Reserve University researchers have discovered a novel population of neutrophils, which are the body's infection control workhorses. These cells have an enhanced microbial killing ability and are thereby better able to control infection.

25 Mar 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

Antares Pharma, Inc. today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

News outlets report on the creative outreach efforts, including those geared to moms, young people and Latinos, to increase the number of newly insured people before March 31. Even prison inmates are signing up.

11 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

The incidence of autism spectrum disorders has increased sharply since it was first described 60 years ago. Today, ASD affects more than 1% of all children in the U.S. and about half of them develop a life-long disability.

3 Mar 2014

Researchers discover novel treatments for psoriasis that are likely to cause fewer side effects

Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis.

28 Feb 2014

Waiting room time helps in effective screening for depression and anxiety

A new study in General Hospital Psychiatry finds patients visiting the hospital for a variety of ailments can be easily screened for depression and anxiety as they wait for care, information that can then be sent immediately to their doctor to address.

27 Feb 2014

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Researchers have long known that people with autoimmune diseases, such as hepatitis, type 1 diabetes, multiple sclerosis and psoriasis, are at greater risk of developing schizophrenia.

24 Feb 2014

Research sheds light on pathological mechanisms that trigger psoriasis lesions

Streptococcal antigens (Streptococcus pyogenes) might be directly involved in the pathological mechanisms that result in the appearance of psoriasis lesions.

21 Feb 2014

XenoPort reports net loss of $19.1 million for fourth quarter 2013

XenoPort, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.

20 Feb 2014

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.

18 Feb 2014

New research identifies raised risk of self-harm among patients with certain physical illnesses

New research quantifying the risk of admission to hospital for self-harm has identified a raised risk of self-harm among groups of patients with certain physical illnesses. While it is known that psychiatric illnesses are associated with a greatly elevated risk of self-harm, a moderately elevated risk was seen with common physical illnesses such as diabetes, epilepsy and asthma.

13 Feb 2014

Psoriasis News and Research

Latest Psoriasis News and Research

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

New initiative aims to develop Global Psoriasis Atlas

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

Patients with autoimmune disease have 3.8-fold increased risk of developing epilepsy

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Researchers discover novel population of neutrophils that exhibit enhanced microbial killing activity

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

Antares Pharma reports total revenue of $4.7 million for fourth quarter 2013

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

Antares Pharma announces launch of OTREXUP to Dermatologists

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

Researchers discover novel treatments for psoriasis that are likely to cause fewer side effects

Waiting room time helps in effective screening for depression and anxiety

People suffering from schizophrenia at greater risk of developing autoimmune diseases

Research sheds light on pathological mechanisms that trigger psoriasis lesions

XenoPort reports net loss of $19.1 million for fourth quarter 2013

Researchers detail how psoralen blocks signaling pathway of HER2-positive cancers

New research identifies raised risk of self-harm among patients with certain physical illnesses

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Psoriasis News and Research

Latest Psoriasis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in